36.58
price down icon2.30%   -0.86
after-market After Hours: 36.75 0.17 +0.46%
loading
Palvella Therapeutics Inc stock is traded at $36.58, with a volume of 90,854. It is down -2.30% in the last 24 hours and up +62.29% over the past month. Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
See More
Previous Close:
$37.44
Open:
$36.8
24h Volume:
90,854
Relative Volume:
0.77
Market Cap:
$404.42M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-5.31%
1M Performance:
+62.29%
6M Performance:
+181.38%
1Y Performance:
+0.00%
1-Day Range:
Value
$36.50
$38.46
1-Week Range:
Value
$36.50
$40.50
52-Week Range:
Value
$11.17
$40.50

Palvella Therapeutics Inc Stock (PVLA) Company Profile

Name
Name
Palvella Therapeutics Inc
Name
Phone
(484) 253-1461
Name
Address
125 STRAFFORD AVE, WAYNE
Name
Employee
14
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
PVLA's Discussions on Twitter

Compare PVLA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
PVLA
Palvella Therapeutics Inc
36.58 413.92M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
456.87 120.48B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.46 59.88B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
392.24 44.31B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
670.33 36.65B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
301.13 32.46B 3.81B -644.79M -669.77M -6.24

Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-21-25 Initiated Truist Buy
Apr-09-25 Initiated Chardan Capital Markets Buy
Mar-26-25 Initiated Stifel Buy
Mar-07-25 Initiated Scotiabank Sector Outperform
Feb-20-25 Initiated Canaccord Genuity Buy
Feb-05-25 Initiated TD Cowen Buy
Dec-26-24 Initiated H.C. Wainwright Buy
Dec-18-24 Initiated Cantor Fitzgerald Overweight
Mar-13-20 Upgrade Robert W. Baird Neutral → Outperform
Jul-30-19 Downgrade Robert W. Baird Outperform → Neutral
May-14-19 Initiated Robert W. Baird Outperform
Mar-19-18 Initiated Evercore ISI Outperform
Mar-19-18 Initiated Jefferies Buy
Jan-16-18 Reiterated H.C. Wainwright Buy
May-30-17 Initiated Rodman & Renshaw Buy
Aug-05-16 Resumed ROTH Capital Buy
Aug-12-15 Initiated JMP Securities Mkt Outperform
Jul-27-15 Initiated Oppenheimer Outperform
Jul-22-15 Initiated ROTH Capital Buy
View All

Palvella Therapeutics Inc Stock (PVLA) Latest News

pulisher
Jul 31, 2025

Is Palvella Therapeutics Inc. a growth stock or a value stockPost Market Growth Plan With High Returns - jammulinksnews.com

Jul 31, 2025
pulisher
Jul 31, 2025

Brokerages Set Palvella Therapeutics, Inc. (NASDAQ:PVLA) Target Price at $47.50 - Defense World

Jul 31, 2025
pulisher
Jul 31, 2025

Volume spikes in Palvella Therapeutics Inc. stock – what they meanWeekly Growth Portfolio Performance Summary - Newser

Jul 31, 2025
pulisher
Jul 31, 2025

Detecting price anomalies in Palvella Therapeutics Inc. with AIReal Time Alerts Based on AI Prediction Triggered - metal.it

Jul 31, 2025
pulisher
Jul 31, 2025

Will Palvella Therapeutics Inc. stock split in the near futureSwing Watchlist With Tight Stop Placement - Newser

Jul 31, 2025
pulisher
Jul 31, 2025

How to read the order book for Palvella Therapeutics Inc.Secure Asset Flow and Trend Pattern Analysis - Newser

Jul 31, 2025
pulisher
Jul 30, 2025

Palvella Therapeutics Inc. stock trend forecastFree Stock Selection With High Accuracy - Newser

Jul 30, 2025
pulisher
Jul 30, 2025

Gorlin Syndrome Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Palvella Therapeutics, Inc., PellePharm, Ascend Biopharmaceuticals - Barchart.com

Jul 30, 2025
pulisher
Jul 30, 2025

Exit strategy if you’re trapped in Palvella Therapeutics Inc.Swing Trade Timing with Daily Forecast - Newser

Jul 30, 2025
pulisher
Jul 30, 2025

Ranking Palvella Therapeutics Inc. among high performing stocks via toolsWeekly Trend Watch with Market Signals - Newser

Jul 30, 2025
pulisher
Jul 30, 2025

Is Palvella Therapeutics Inc. Stock Overbought or Oversold RSI Indicator AnalysisAutomated AI Forecast with Trading Alerts - Newser

Jul 30, 2025
pulisher
Jul 28, 2025

What makes Palvella Therapeutics Inc. stock price move sharplyPost Market Trend Scanner For Smart Trading - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Should I hold or sell Palvella Therapeutics Inc. stock in 2025Explosive capital gains - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What is the risk reward ratio of investing in Palvella Therapeutics Inc. stockSuperior portfolio returns - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How does Palvella Therapeutics Inc. compare to its industry peersGet expert analysis on top stock picks - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

When is Palvella Therapeutics Inc. stock expected to show significant growthFree Investment Case Studies - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Ranking Palvella Therapeutics Inc. among high performing stocks via tools Investment Life Cycle Planning Summary - Newser

Jul 28, 2025
pulisher
Jul 28, 2025

How does Palvella Therapeutics Inc. generate profit in a changing economyExplosive earning power - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What catalysts could drive Palvella Therapeutics Inc. stock higher in 2025Capital growth strategies that work - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

Is Palvella Therapeutics Inc. stock overvalued or undervaluedDiscover stocks with superior performance - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Key External Factors That Drive Palvella Therapeutics Inc. Stock Price MovementsFree Access to Investment Community - metal.it

Jul 27, 2025
pulisher
Jul 27, 2025

Will Palvella Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsBreakout Confirmation Tool - Newser

Jul 27, 2025
pulisher
Jul 27, 2025

Is it the right time to buy Palvella Therapeutics Inc. stockIdentify undervalued stocks poised to rally - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Top Risks to Consider Before Buying Palvella Therapeutics Inc. StockFree Stock Market Knowledge Sharing - Newser

Jul 27, 2025
pulisher
Jul 27, 2025

Palvella Therapeutics Inc. Stock Performance After Earnings: Historical InsightsMinimized Risk Maximum Return - Newser

Jul 27, 2025
pulisher
Jul 27, 2025

Top Risks to Consider Before Buying Palvella Therapeutics Inc. Stock Free Consistent Gain Investment Strategies - Newser

Jul 27, 2025
pulisher
Jul 25, 2025

Palvella Therapeutics Inc. Stock Analysis and ForecastConsistently outstanding ROI - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What drives Palvella Therapeutics Inc. stock priceUnprecedented profit potential - Autocar Professional

Jul 25, 2025
pulisher
Jul 25, 2025

Is Palvella Therapeutics Inc. a good long term investmentFree Capital Allocation Plans - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Why Palvella Therapeutics Inc. stock attracts strong analyst attentionSafer Investing With Bigger Upside - Newser

Jul 25, 2025
pulisher
Jul 24, 2025

Should I buy Palvella Therapeutics Inc. stock before earningsTriple-digit wealth increases - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 23, 2025

What analysts say about Palvella Therapeutics Inc. stockStrong return on investment - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

A Great Week for Institutional Investors Who Own 27% of Palvella Therapeutics, Inc. (NASDAQ:PVLA) - 富途牛牛

Jul 23, 2025
pulisher
Jul 23, 2025

Palvella Therapeutics Inc (PVLA) Stock: A Year of Highs and Lows in the Market - investchronicle.com

Jul 23, 2025

Palvella Therapeutics Inc Stock (PVLA) Financials Data

There is no financial data for Palvella Therapeutics Inc (PVLA). Check out other stocks for more information.

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$74.89
price down icon 3.43%
$36.80
price down icon 0.86%
$107.28
price up icon 2.00%
$26.37
price down icon 1.09%
$107.50
price down icon 2.32%
biotechnology ONC
$301.13
price up icon 0.40%
Cap:     |  Volume (24h):